Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFJXDZ)

Drug Name
IGM-8444 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMFJXDZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TRAIL receptor 2 (TRAIL-R2) TTW20TU TR10B_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TRAIL receptor 2 (TRAIL-R2) DTT TNFRSF10B 5.914 2.963 5.311 3.744
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hematologic tumour
ICD Disease Classification 2B33.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TRAIL receptor 2 (TRAIL-R2) DTT TNFRSF10B 1.03E-05 1.09 4.71
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04553692) Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of IGM Biosciences.